Deepika Reddy

Dr. Deepika Reddy

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2022 in European Urology
Verified
Journal Article
Closed access
DRDeepika Reddy
Deepika Reddy
MPMax Peters
Max Peters
TSTaimur T. Shah
Taimur T. Shah
MSMarieke van Son
Marieke van Son
MTMariana Bertoncelli Tanaka
Mariana Bertoncelli Tanaka
HAHashim U. Ahmed
Hashim U. Ahmed

10 November 2022 in BJU International
Verified
Journal Article
Open access
DEDavid Eldred‐Evans
David Eldred‐Evans
MCMartin J. Connor
Martin J. Connor
MTMariana Bertoncelli Tanaka
Mariana Bertoncelli Tanaka
EBEdward Bass
Edward Bass
DRDeepika Reddy
Deepika Reddy
HAHashim Uddin Ahmed
Hashim Uddin Ahmed
Objective: To report outcomes within the Rapid Assessment for Prostate Imaging and Diagnosis (RAPID) diagnostic pathway, introduced to reduce patient and healthcare burdens and standardize delivery of pre‐biopsy multiparametric magnetic resonance imaging (MRI) and transperineal biopsy. Patients and Methods: A total of 2130 patients from three centres who completed the RAPID pathway (3 April 2017 to 31 March 2020) were consecutively entered as a prospective registry. These patients were also compared to a pre‐RAPID cohort of 2435 patients. Patients on the RAPID pathway with an MRI score 4 or 5 and those with PSA density ≥0.12 and an MRI score 3 were advised to undergo a biopsy. Primary outcomes were rates of biopsy and cancer detection. Secondary outcomes included comparison of transperineal biopsy techniques, patient acceptability and changes in time to diagnosis before and after the introduction of RAPID. Results: The median patient age and PSA level were 66 years and 6.6 ng/mL, respectively. Biopsy could be omitted in 43% of patients (920/2130). A further 7.9% of patients (168/2130) declined a recommendation for biopsy. The percentage of biopsies avoided among sites varied (45% vs 36% vs 51%; P < 0.001). In all, 30% (221/742) had a local anaesthetic (grid and stepper) transperineal biopsy. Clinically significant cancer detection (any Gleason score ≥3 + 4) was 26% (560/2130) and detection of Gleason score 3 + 3 alone constituted 5.8% (124/2130); detection of Gleason score 3 + 3 did not significantly vary among sites ( P = 0.7). Among participants who received a transperineal targeted biopsy, there was no difference in cancer detection rates among local anaesthetic, sedation and general anaesthetic groups. In the 2435 patients from the pre‐RAPID cohor, time to diagnosis was 32.1 days (95% confidence interval [CI] 29.3–34.9) compared to 15.9 days (95% CI 12.9–34.9) in the RAPID group. A total of 141 consecutive patient satisfaction surveys indicated a high satisfaction rate with the pathway; 50% indicated a preference for having all tests on a single day. Conclusions: The RAPID prostate cancer diagnostic pathway allows 43% of men to avoid a biopsy while preserving good detection of clinically significant cancers and low detection of insignificant cancers, although there were some centre‐level variations.

1 June 2020 in Contemporary Clinical Trials
Verified
Journal Article
Closed access
DRDeepika Reddy
Deepika Reddy
TSTaimur T. Shah
Taimur T. Shah
TDTim Dudderidge
Tim Dudderidge
SMStuart McCracken
Stuart McCracken
MAManit Arya
Manit Arya
HAHashim U. Ahmed
Hashim U. Ahmed

8 September 2023 in Journal of Medical Economics
Verified
Journal Article
Open access
DRDeepika Reddy
Deepika Reddy
MSMarieke Van Son
Marieke Van Son
MPMax Peters
Max Peters
MTMariana Bertoncelli Tanaka
Mariana Bertoncelli Tanaka
TDTim Dudderidge
Tim Dudderidge
HAHashim Uddin Ahmed
Hashim Uddin Ahmed
Focal therapy treats individual areas of tumour in non-metastatic prostate cancer in patients unsuitable for active surveillance. The aim of this work was to evaluate the cost-effectiveness of focal therapy versus prostatectomy and external beam radiotherapy (EBRT). A Markov cohort health state transition model with four health states (stable disease, local recurrence, metastatic disease and death) was created, evaluating costs and utilities over a 10-year time horizon for patients diagnosed with non-metastatic prostate cancer. National Health Service (NHS) for England perspective was used, based on direct healthcare costs. Clinical transition probabilities were derived from prostate cancer registries in patients undergoing radical prostatectomy, EBRT and focal therapy using cryotherapy (Boston Scientific) or high-intensity focused ultrasound (HIFU) (Sonablate). Propensity score matching was used to ensure at-risk populations were comparable. Variables included age, prostate-specific antigen (PSA), International Society of Urological Pathology (ISUP) grade group, maximum cancer core length (mm), T-stage and year of treatment. Focal therapy was associated with a lower overall cost and higher quality adjusted life year (QALY) gains than either prostatectomy or EBRT, dominating both treatment strategies. Positive incremental net monetary benefit (NMB) values confirm focal therapy as cost effective versus the alternatives at a willingness to pay (WTP) threshold of £30,000/QALY. One-way deterministic sensitivity analyses revealed consistent results. Data used to calculate the transition probabilities were derived from a limited number of hospitals meaning that other potential treatment options were excluded. Limited data were available on later outcomes and none on quality of life data, therefore, literature-based estimates were used. Cost-effectiveness modelling demonstrates use of focal therapy (cryotherapy or HIFU) is associated with greater QALY gains at a lower overall cost than either radical prostatectomy or EBRT, representing good value for money in the NHS.

28 December 2024 in Current Oncology
Verified
Journal Article
Open access
PDF file
FLFrancesco Lasorsa
Francesco Lasorsa
ABArianna Biasatti
Arianna Biasatti
AOAngelo Orsini
Angelo Orsini
GBGabriele Bignante
Gabriele Bignante
GFGabriana M. Farah
Gabriana M. Farah
SVSrinivas Vourganti
Srinivas Vourganti
Focal therapy has emerged as a balanced middle ground aiming to reduce overtreatment and the risk of progression, as well as patients’ distress and anxiety. Focal therapy and partial gland ablation prioritize the precise elimination of the index lesion and a surrounding safety margin to optimize treatment outcomes and lower the risk of residual disease. The paradigm of whole-gland ablation has shifted towards more targeted approaches. Several treatment templates ranging from subtotal and hemiablation to “hockey-stick”, quadrant, and even focal lesion ablation have emerged. Many types of energy may be utilized during focal treatment. First, focal therapy can be grossly classified into thermal vs. non-thermal energy. The aim of this non-systematic review is to offer a comprehensive analysis of recently available evidence on focal therapy for PCa.

1 June 2020 in Translational Andrology and Urology
Verified
Journal Article
Open access
PDF file
DRDeepika Reddy
Deepika Reddy
NBNishant Bedi
Nishant Bedi
TDTim Dudderidge
Tim Dudderidge
Organ preserving management is common place in renal cancer, breast cancer and many other solid organ tumours. Current strategies in managing intermediate risk prostate cancer include either whole gland treatment, in the form of radical radiotherapy or radical prostatectomy, or active surveillance. The former is associated with significant post-treatment functional morbidity, whilst the latter associated with the burden of surveillance activity and patient anxiety. Focal therapy would logically fit as a middle ground for suitable patients in whom treatment would be recommended, but where much better functional outcomes may be possible. Ideally this comes without restricting the successful prevention of harm from the cancer. Historically limitations in developing tissue preserving focal therapy strategies in prostate cancer, were due to inaccuracies in tumour characterisation prior to treatment and during follow up. Consequently for example many patients undergoing an active surveillance strategy were being upgraded and upstaged within a short period. Recently high level evidence supporting the use of MRI and targeted biopsies, in particular the PROMIS and PRECISION trials have strengthened clinician confidence in accurate disease characterisation, thus making focal therapy to become a more feasible management option. With improved diagnostic strategies and the publication of reassuring medium term oncological and functional outcomes after focal therapy for intermediate risk prostate cancer, has the time come to require consideration of focal therapy within our multi-disciplinary team (MDT) meetings and with patients? In this review we will consider patient selection and the evidence for the various focal ablation options as well as the surveillance of these patients after treatment. The forthcoming trials to determine comparative effectiveness will be discussed.